secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0000950170-23-042420
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences Q2 net loss $12.8M; reports positive PCOS interim data
-------------------------------------------------------------------------

- Net loss of $12.8M for Q2 2023 vs $11.9M for Q2 2022; six-month loss $25.6M.
- Cash, equivalents and investments of $120.5M; expected to fund operations into H1 2025.
- Collaboration revenue $2.2M from Kaken Pharmaceutical upfront payment recognition.
- Interim Phase 2 PCOS data (20 patients) suggests DHEAS reduction with tildacerfont; no serious AEs.
- CAHmelia-203 enrollment >75%; CAHmelia-204 nearing 75%; CAHptain cohort 3 screening underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000095017023042420/0000950170-23-042420-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000095017023042420/sprb-20230814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-042420

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer